Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Digital Imaging System Offers Superior Multiple-Biomarker Tissue Analysis

By BiotechDaily International staff writers
Posted on 09 Apr 2012
Image: Tissue IA 2.0 – Automated Image Analysis for Brightfield and Fluorescence Digital Pathology (Photo courtesy of Leica Microsystems).
Image: Tissue IA 2.0 – Automated Image Analysis for Brightfield and Fluorescence Digital Pathology (Photo courtesy of Leica Microsystems).
The Tissue IA 2.0 image analysis system provides pathology researchers with superior capability for immunohistochemistry (IHC) biomarker quantification and tissue localization. The system provides a unique combination of flexibility, automation, and ease-of-use that make it an excellent tool for discovery and translational research in pathology.

Developed and released by Leica Microsystems (Leica; Wetzlar, Germany), the research-only system, Tissue IA 2.0 features fluorescence and brightfield analysis capabilities in a single platform as well as precision cell modeling. Advanced dual staining capabilities enable researchers to identify cell cohorts at the molecular level. Use one marker to identify a population of interest and then quantify expression using a second, providing greater understanding of sample slides. Algorithms are easily adjusted and optimized for different markers, tissue, and protocols, giving a flexible platform, also for drug discovery applications.

Tissue IA 2.0 provides expert tools for retrieval of quantitative, reproducible data from tissue-based IHC studies. Powerful color separation and multimarker co-localization functionality provides advanced insight and unbiased measurement of multiple antigen immunostaining in brightfield or fluorescent samples. Sophisticated cell modeling accurately detects and quantifies differential expression of staining in cellular compartments, providing detailed insight into cytoplasmic, membrane, and nuclear biomarker localization.

“Mulitplexing is of growing importance in translational research and tools to help quantify the expression and location of multiple biomarkers concurrently in tissue are a real requirement. TissueIA 2.0 delivers for the user through offering chromogenic and fluorescence quantification and co-localization, cell based histoscoring on multicompartmental IHC staining and the power to include and exclude cell populations based on biomarker expression. In conjunction with our SCN400 F and Ariol platforms, this further expands our Digital Pathology portfolio for the life science and clinical researcher and demonstrates our ongoing commitment to this area,” said Dr. Donal O’Shea, Head of Digital Pathology in Leica Microsystems. With Tissue IA 2.0, Leica's Digital Pathology portfolio provides streamlined end-to-end excellence in capture, management, and analysis of digital pathology images.

With high throughput batch analysis capacity, Tissue IA 2.0 will process whole slides, regions of interest or tissue microarray cores, and automatically integrate analysis results with user’s slides. A built-in upload interface facilitating integration of algorithms from third party software solutions, gives greater flexibility to further expand analysis options. The system includes a web-accessible interface, enabling users to take their analyses wherever they go.

Leica Microsystems will be at the American Association for Cancer Research Annual Meeting 2012, March 31 to April 4, Chicago, IL. Visit booth 4103 to experience this new image analysis solution for Digital Pathology.


Related Links:
Leica Microsystems
Tissue IA 2.0



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.